We are live on ! Find out more
TGI

TRV GP II Portfolio holdings

AUM $1.34M
1-Year Est. Return 67.55%
This Fund
S&P 500
This Quarter Est. Return
+0.53%
1 Year Est. Return
-67.55%
3 Year Est. Return
-20.84%
5 Year Est. Return
-49.87%
10 Year Est. Return
–
AUM
$144M
AUM Growth
-$10.5M
Cap. Flow
-$8.02M
Cap. Flow %
-5.58%
Top 10 Hldgs %
100%
Holding
3
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$8.02M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$39.9B
$75.6M 52.65%
1,909,317
– –
JNCE
2
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$64.4M 44.86%
9,200,349
-1,030,000
-10% -$8.02M
ALNA
3
DELISTED
Allena Pharmaceuticals
ALNA
$3.57M 2.49%
2,790,964
– –

Similar funds

IVAV
Index Venture Associates V St. Helier, Channel Islands, Jersey $1.46M AUM 88.05% 1-Year Est. Return
VM
Value Monitoring Menlo Park, California $1.5M AUM 13.21% 1-Year Est. Return
CL
CRV LLC Palo Alto, California $1.56M AUM 87.36% 1-Year Est. Return
GAM
GVO Asset Management Zug, Switzerland $1.07M AUM 24.36% 1-Year Est. Return
MC
Manteio Capital Jersey City, New Jersey $1.05M AUM
NC
Noked Capital Tel Aviv, Israel $946K AUM 17.1% 1-Year Est. Return
HCIG
H Capital II GP Grand Cayman, Cayman Islands $1.83M AUM
NP
Nimble Partners San Francisco, California $556K AUM 61.7% 1-Year Est. Return

TRV GP II's Q4 2020 Portfolio in Review

As of Q4 2020, TRV GP II held 3 positions worth $144M, down 6.8% from $154M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP II withdrew a net $8.02M in Q4 2020, reducing 1 holding. Its largest reduction was Jounce Therapeutics, Inc. Common Stock, cutting an estimated $8.02M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP II's biggest Q4 2020 reduction was Jounce Therapeutics, Inc. Common Stock, cutting an estimated $8.02M.
  • TRV GP II's ten largest holdings make up 100% of its $144M portfolio in Q4 2020.
  • TRV GP II opened 0 new positions and closed 0 in Q4 2020.
  • TRV GP II's portfolio value fell 6.8% quarter-over-quarter to $144M.

Based on TRV GP II's 13F filing for Q4 2020, filed 16 Feb 2021.